Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.56 USD | -2.50% | +1.30% | 0.00% |
May. 13 | Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 06 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 10.17M | Capitalization | 220M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -71M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 21.6 x |
P/E ratio 2024 * |
-4.17
x | P/E ratio 2025 * |
-3.67
x | Employees | 32 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.96% |
1 day | -2.50% | ||
1 week | -3.41% | ||
Current month | +8.33% | ||
1 month | +6.12% | ||
3 months | -13.33% | ||
6 months | -7.69% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 16-12-31 | |
Thomas Schuetz
FOU | Founder | 63 | 13-12-31 |
Neil Lerner
DFI | Director of Finance/CFO | 56 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Lindahl
BRD | Director/Board Member | 70 | 23-04-20 |
Mary Gray
BRD | Director/Board Member | 71 | 22-04-24 |
Ellen Chiniara
BRD | Director/Board Member | 65 | 22-04-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +4.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 1.56 | -2.50% | 100,823 |
24-05-21 | 1.6 | 0.00% | 137,213 |
24-05-20 | 1.6 | 0.00% | 99,406 |
24-05-17 | 1.6 | 0.00% | 181,395 |
24-05-16 | 1.6 | +3.90% | 301,574 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 220M | |
+9.99% | 114B | |
+12.01% | 107B | |
-3.07% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.90% | 17.51B | |
-39.36% | 17.17B | |
+5.82% | 14.14B | |
+33.05% | 12.2B |
- Stock Market
- Equities
- CMPX Stock